{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:26:32Z","timestamp":1787390792084,"version":"build-2736575974"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clon.2026.104281","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:33:28Z","timestamp":1782491608000},"page":"104281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Neoadjuvant and Adjuvant Strategies"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1364-5508","authenticated-orcid":false,"given":"C.V.","family":"Suartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.M.T.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-0225","authenticated-orcid":false,"given":"P.H. de S.","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6969-5019","authenticated-orcid":false,"given":"A.P.S.","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3342-6394","authenticated-orcid":false,"given":"L.S.","family":"de almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7015-6740","authenticated-orcid":false,"given":"B.","family":"Liebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.B.B.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.V.H.","family":"Sant\u2019Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8569-2440","authenticated-orcid":false,"given":"V.D.F.","family":"de Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-414X","authenticated-orcid":false,"given":"L.O.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.C.","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8439-3283","authenticated-orcid":false,"given":"M.C.","family":"Dener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Shahrour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Shabana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Ribeiro-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clon.2026.104281_bib1","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA: A Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clon.2026.104281_bib2","first-page":"75","article-title":"EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2024 guidelines","volume":"85","author":"Witjes","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clon.2026.104281_bib3","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clon.2026.104281_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"New England J Med"},{"issue":"9373","key":"10.1016\/j.clon.2026.104281_bib5","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.clon.2026.104281_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis","volume":"48","author":"Vale","year":"2005","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.clon.2026.104281_bib7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for cisplatin-based adjuvant chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clon.2026.104281_bib8","article-title":"The perioperative revolution in muscle-invasive bladder cancer: Progress, caution, and the Latin American perspective","volume":"52","author":"Suartz","year":"2026","journal-title":"Int Brazilian J Urol"},{"issue":"1","key":"10.1016\/j.clon.2026.104281_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3\u2013pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): An intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.clon.2026.104281_bib10","first-page":"1850","article-title":"Adjuvant chemotherapy for bladder cancer: A population-based outcome study","volume":"32","author":"Booth","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clon.2026.104281_bib11","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"New England J Med"},{"issue":"10122","key":"10.1016\/j.clon.2026.104281_bib12","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clon.2026.104281_bib13","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2026.104281_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.euros.2025.07.010","article-title":"Neoadjuvant immunotherapy in bladder cancer: Ushering in a new era of treatment\u2014A systematic review of current evidence","volume":"79","author":"Suartz","year":"2025","journal-title":"Eur Urol Open Sci"},{"issue":"21","key":"10.1016\/j.clon.2026.104281_bib15","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"New England J Med"},{"issue":"2","key":"10.1016\/j.clon.2026.104281_bib16","first-page":"214","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable muscle-invasive bladder cancer","volume":"76","author":"Powles","year":"2019","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.clon.2026.104281_bib17","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo after radical surgery in muscle-invasive urothelial carcinoma (CheckMate 274)","volume":"384","author":"Bajorin","year":"2021","journal-title":"New England J Med"},{"issue":"7867","key":"10.1016\/j.clon.2026.104281_bib18","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.clon.2026.104281_bib19","series-title":"Study of neoadjuvant ipilimumab in patients with urothelial carcinoma undergoing surgical resection. ClinicalTrials.gov Identifier: NCT00362713","author":"Bristol-Myers","year":"2006"},{"issue":"3","key":"10.1016\/j.clon.2026.104281_bib20","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.eururo.2013.10.056","article-title":"Perioperative chemotherapy in muscle-invasive bladder cancer: Overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial","volume":"65","author":"Colombel","year":"2014","journal-title":"Eur Urol"},{"issue":"6 Suppl","key":"10.1016\/j.clon.2026.104281_bib21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2023.41.6_suppl.448","article-title":"HCRN GU14-188: Phase Ib\/II study of neoadjuvant pembrolizumab and chemotherapy for T2-4aN0M0 urothelial cancer","volume":"41","author":"Brown","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clon.2026.104281_bib22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Uro"},{"issue":"2","key":"10.1016\/j.clon.2026.104281_bib23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clon.2026.104281_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.clon.2026.104281_bib25","article-title":"Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423)","volume":"39","author":"Natesan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.clon.2026.104281_bib26","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clon.2026.104281_bib27","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: A multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104281_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"New England J Med"},{"issue":"23","key":"10.1016\/j.clon.2026.104281_bib29","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.clon.2026.104281_bib30","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"issue":"6 Suppl","key":"10.1016\/j.clon.2026.104281_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2022.40.6_suppl.535","article-title":"Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma","volume":"40","author":"Goubet","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clon.2026.104281_bib32","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: The NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"issue":"6 Suppl","key":"10.1016\/j.clon.2026.104281_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle-invasive bladder cancer undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clon.2026.104281_bib34","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1158\/1078-0432.CCR-25-3771","article-title":"Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer","volume":"32","author":"Guercio","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"33","key":"10.1016\/j.clon.2026.104281_bib35","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1200\/JCO.23.00363","article-title":"Perioperative chemoimmunotherapy with durvalumab for muscle-invasive urothelial carcinoma: Primary analysis of the single-arm phase II trial SAKK 06\/17","volume":"41","author":"Cathomas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104281_bib36","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1186\/s12885-021-08990-3","article-title":"Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle-invasive bladder cancer: A multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)","volume":"21","author":"Martinez Chanza","year":"2021","journal-title":"BMC Cancer"},{"issue":"6 Suppl","key":"10.1016\/j.clon.2026.104281_bib37","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2023.41.6_suppl.447","article-title":"Co-primary endpoint analysis of HCRN GU 16-257: Phase II trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer","volume":"41","author":"Galsky","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.clon.2026.104281_bib38","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.1200\/JCO.2020.38.15_suppl.5012","article-title":"DUTRENEO Trial: A randomized phase II trial of durvalumab and tremelimumab versus chemotherapy as a neoadjuvant approach to muscle-invasive urothelial bladder cancer patients prospectively selected by an interferon-gamma immune signature","volume":"38","author":"Grande","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.clon.2026.104281_bib39","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2020.38.6_suppl.542","article-title":"Impact of the combination of durvalumab plus olaparib administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB trial","volume":"38","author":"Rodriguez-Moreno","year":"2020","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clon.2026.104281_bib40","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"New England J Med"},{"key":"10.1016\/j.clon.2026.104281_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1013","article-title":"Durvalumab with or without tremelimumab in combination with dose-dense MVAC as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma: Results of NEMIO, a randomized phase I\u2013II trial","volume":"34","author":"Thibault","year":"2023","journal-title":"Annals Oncol"},{"key":"10.1016\/j.clon.2026.104281_bib42","series-title":"A window-of-opportunity trial of avelumab in nonmetastatic muscle-invasive bladder cancer. ClinicalTrials.gov Identifier: NCT03498196","author":"Taylor","year":"2018"},{"issue":"6 Suppl","key":"10.1016\/j.clon.2026.104281_bib43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2020.38.6_suppl.507","article-title":"Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2","volume":"38","author":"Wei","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104281_bib44","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.euo.2023.11.022","article-title":"PrECOG PrE0807: A phase 1b feasibility trial of neoadjuvant nivolumab without and with lirilumab in patients with muscle-invasive bladder cancer ineligible for or refusing cisplatin-based neoadjuvant chemotherapy","volume":"7","author":"Grivas","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.clon.2026.104281_bib45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2023.41.6_suppl.524","article-title":"Phase II open-label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer","volume":"41","author":"Khaki","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.clon.2026.104281_bib46","doi-asserted-by":"crossref","first-page":"TPS596","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS596","article-title":"PIVOT IO 009: A phase III randomized study of neoadjuvant and adjuvant nivolumab plus bempegaldesleukin versus nivolumab alone versus standard of care in cisplatin-ineligible muscle-invasive bladder cancer","volume":"40","author":"Grivas","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.clon.2026.104281_bib47","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1200\/JCO.2022.40.16_suppl.4589","article-title":"Phase II clinical study of tislelizumab combined with nab-paclitaxel for muscle-invasive urothelial bladder carcinoma: Bladder preservation subgroup analysis","volume":"40","author":"Niu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.clon.2026.104281_bib48","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2024.42.4_suppl.619","article-title":"Tislelizumab in combination with gemcitabine plus cisplatin as neoadjuvant therapy for lymph node-positive bladder cancer: Results of a prospective study","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104281_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.33696\/cancerimmunol.6.081","article-title":"Perioperative immune checkpoint blockade for muscle-invasive and metastatic bladder cancer","volume":"6","author":"Ramamurthy","year":"2024","journal-title":"J Cancer Immunol"},{"issue":"16 Suppl","key":"10.1016\/j.clon.2026.104281_bib50","article-title":"Phase Ib neoadjuvant CG0070 and nivolumab for cisplatin-ineligible muscle-invasive bladder cancer","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.clon.2026.104281_bib51","article-title":"A phase II study of toripalimab combined with gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer","volume":"41","author":"Xu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.clon.2026.104281_bib52","article-title":"A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial muscle-invasive bladder cancer (ABACUS-2)","volume":"34","author":"Szabados","year":"2023","journal-title":"Annals Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.clon.2026.104281_bib53","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1200\/JCO.2024.42.4_suppl.596","article-title":"Bladder-sparing treatment for muscle-invasive bladder carcinoma: A single-center, single-arm clinical study of sequential neoadjuvant chemotherapy followed by tislelizumab neoadjuvant immunotherapy","volume":"42","author":"Zeng","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.clon.2026.104281_bib54","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2024.42.4_suppl.632","article-title":"Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer: Interim analysis of ANTICIPATE phase II trial","volume":"42","author":"Galsky","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.clon.2026.104281_bib55","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2024.42.4_suppl.632","article-title":"Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer: Interim analysis of ANTICIPATE phase II trial","volume":"42","author":"Galsky","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.clon.2026.104281_bib56","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1200\/JCO.2024.42.4_suppl.610","article-title":"First results of NURE-Combo: A phase II study of neoadjuvant nivolumab and nab-paclitaxel followed by postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer","volume":"42","author":"Mercinelli","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clon.2026.104281_bib57","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S1470-2045(25)00358-4","volume":"26","author":"Necchi","year":"2025","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.clon.2026.104281_bib58","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"New England J Med"},{"issue":"7 Suppl","key":"10.1016\/j.clon.2026.104281_bib59","first-page":"LBA630","article-title":"Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab for participants with muscle-invasive bladder cancer who are eligible for cisplatin: Randomized, open-label, phase III KEYNOTE-B15 study","volume":"44","author":"Galsky","year":"2026","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104281_bib60","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S1470-2045(26)00050-1","article-title":"Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): A single-arm, phase 2 study","volume":"27","author":"Necchi","year":"2026","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clon.2026.104281_bib61","first-page":"55","article-title":"Clinical practice recommendations for the perioperative management of muscle-invasive bladder cancer","volume":"82","author":"Witjes","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clon.2026.104281_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2026.03.005","article-title":"Blood and urine circulating tumor DNA in urothelial bladder cancer: State of the art and clinical perspective","author":"Duquesne","year":"2026","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10.1016\/j.clon.2026.104281_bib63","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41591-026-04271-3","article-title":"Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: A phase 2 trial","volume":"32","author":"Mellema","year":"2026","journal-title":"Nat Medi"},{"issue":"3","key":"10.1016\/j.clon.2026.104281_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102087","article-title":"Honing the hunt: A comprehensive review of cell-free tumor DNA to predict neoadjuvant therapy efficacy in bladder cancer","volume":"22","author":"Suartz","year":"2024","journal-title":"Clin Genitourinary Cancer"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526002529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:54:52Z","timestamp":1787388892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526002529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":64,"alternative-id":["S0936655526002529"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104281","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Neoadjuvant and Adjuvant Strategies","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"104281"}}